Effect of drug chirality on the skin permeability of ibuprofen

The in vitro passive diffusion of S-ibuprofen ( S-IB) and RS-ibuprofen ( RS-IB) through human epidermis was determined to study the effects of drug chirality. S-IB has a lower melting point ( T m = 54 °C) than RS-IB ( T m = 77 °C) and, therefore, a greater solubility ( S-IB: 127 ± 1 μg/mL; RS-IB: 81...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics Vol. 386; no. 1; pp. 71 - 76
Main Authors: Cilurzo, F., Alberti, E., Minghetti, P., Gennari, C.G.M., Casiraghi, A., Montanari, L.
Format: Journal Article
Language:English
Published: Amsterdam Elsevier B.V 15-02-2010
Elsevier
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The in vitro passive diffusion of S-ibuprofen ( S-IB) and RS-ibuprofen ( RS-IB) through human epidermis was determined to study the effects of drug chirality. S-IB has a lower melting point ( T m = 54 °C) than RS-IB ( T m = 77 °C) and, therefore, a greater solubility ( S-IB: 127 ± 1 μg/mL; RS-IB: 81 ± 1 μg/mL). Supersaturated plasters were prepared by using a poly(dimethylsiloxane) adhesive and Eugragit ® RL and propylene glycol as antinucleant agents. The in vitro skin permeation profiles were determined by Franz cells and human epidermis obtained from three different donors. The permeation profiles of S-IB from saturated solutions resulted statistically higher than those of RS-IB ( p < 0.002). When plasters were used, no differences were noticeable between the enantiomer and racemate ( p > 0.17). The latter unexpected results could be explained considering that the RS-IB or S-IB in vitro release rate constants, determined using 3% w/w or 6% w/w loaded plasters, were not statistically different, suggesting that the drug diffusivity within the adhesive matrix represented the rate limiting step to the skin absorption.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2009.10.053